Reverse-phase protein arrays for application-orientated cancer research

Proteomics - Clinical Applications

Volumn 3, Issue 10, 2009, Pages 1140-1150

  Korf, Ulrike ^a   Löbke, Christian ^a   Sahin, Ozgur ^a   Haller, Florian ^b   Sültmann, Holger ^a   Arlt, Dorit ^a   Poustka, Annemarie ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Cancer; Drug discovery; Quantitative biology; Reverse phase protein array; Systems biology

Indexed keywords

CAPECITABINE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; IMATINIB; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; RAS PROTEIN;

BREAST CANCER; CANCER RESEARCH; CARCINOGENESIS; CLINICAL TRIAL; DRUG TARGETING; GASTROINTESTINAL STROMAL TUMOR; GENE EXPRESSION PROFILING; GENE SILENCING; HEAD AND NECK CANCER; HUMAN; IN VITRO STUDY; LUNG CARCINOMA; METASTASIS POTENTIAL; MUTATIONAL ANALYSIS; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN MICROARRAY; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; REVERSE PHASE PROTEIN MICROARRAY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RHABDOMYOSARCOMA; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION;

EID: 70350776980     PISSN: 18628346     EISSN: None     Source Type: Journal    
DOI: 10.1002/prca.200780035     Document Type: Review

References (67)

1. van't Veer, L. J., Dai, H. Y., van de Vijver, M. J., He, Y. D. D. et al., Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415, 530-536.
2. Schneider, J., Ruschhaupt, M., Buness, A., Asslaber, M. et al., Identification and meta-analysis of a small gene expression signature for the diagnosis of estrogen receptor status in invasive ductal breast cancer. Int. J. Cancer 2006, 119, 2974-2979.
3. Gygi, S. P., Rochon, Y., Franza, B. R., Aebersold, R., Correlation between protein and mRNA abundance in yeast. Mol. Cell Biol. 1999, 19, 1720-1730.
4. Anderson, L., Seilhamer, J., A comparison of selected mRNA and protein abundances in human liver. Electrophoresis 1997, 18, 533-537.
5. Paweletz, C. P., Charboneau, L., Bichsel, V. E., Simone, N. L. et al., Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene 2001, 20, 1981-1989.
6. Fountaine, T. J., Wincovitch, S. M., Geho, D. H., Garfield, S. H. et al., Multispectral imaging of clinically relevant cellular targets in tonsil and lymphoid tissue using semiconductor quantum dots. Modern Pathol. 2006, 19, 1181-1191.
7. Shi, C., Zhou, G., Zhu, Y., Su, Y. et al., Quantum dots-based multiplexed immunohistochemistry of protein expression in human prostate cancer cells. Eur. J. Histochem. 2008, 52, 127-133.
8. Washburn, M., Wolters, D., Yates, J. R., Large-scale analysis of the yeast proteome by multidimensional protein identification technology. Nat. Biotechnol. 2001, 19, 242-247.
9. Wu, C., MacCoss, M., Howell, K. Y. J., 3rd., A method for the comprehensive proteomic analysis of membrane proteins. Nat. Biotechnol. 2003, 21, 532-538.
10. Schmidt, A., Kellermann, J., Lottspeich, F., A novel strategy for quantitative proteornics using isotope-coded protein labels. Proteomics 2005, 5, 4-15.
11. Koller, A., Watzig, H., Precision and variance components in quantitative gel electrophoresis. Electrophoresis 2005, 26, 2470-2475.
12. Swameye, I., Muller, T. G., Timmer, J., Sandra, O. et al., Identification of nucleocytoplasmic cycling as a remote sensor in cellular signaling by databased modeling. Proc. Natl. Acad. Sci. USA 2003, 100, 1028-1033.
13. Renart, J., Reiser, J. GR. S., Transfer of proteins from gels to diazobenzyloxymethyl-paper and detection with antisera: a method for studying antibody specificity and antigen structure. Proc. Natl. Acad. Sci. USA 1979, 76, 3116-3120.
14. KauffmanZeh, A., RodriguezViciana, P., Ulrich, E., Gilbert, C. et al., Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB. Nature 1997, 385, 544-548.
15. Myers, M. P., Pass, I., Batty, I. H., Van der Kaay, J. et al., The lipid phosphatase activity of PTEN is critical for its tumor suppressor function. Proc. Natl. Acad. Sci. USA 1998, 95, 13513-13518.
16. Grote, T., Siwak, D. R., Fritsche, H. A., Joy, C. et al., Validation of reverse phase protein array for practical screening of potential biomarkers in serum and plasma: accurate detection of CA19-9 levels in pancreatic cancer. Proteomics 2008, 8, 3051-3060.
17. Stemke-Hale, K., Gonzalez-Angulo, A. M., Lluch, A., Neve, R. M. et al., An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res. 2008, 68, 6084-6091.
18. Stambolic, V., Suzuki, A., de la Pompa, J. L., Brothers, G. M. et al., Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 1998, 95, 29-39.
19. Hunter, T., Oncoprotein networks. Cell 1997, 88, 333-346.
20. Lavoie, J. N., Lallemain, G., Brunet, A., Muller, R. et al., Cyclin D1 expression is regulated positively by the p42/p44(MAPK) and negatively by the p38/HOG(MAPK) pathway. J. Biol. Chem. 1996, 271, 20608-20616.
21. Grubb, R. L., Calvert, V. S., Wulkuhle, J. D., Paweletz, C. P. et al., Signal pathway profiling of prostate cancer using reverse phase protein arrays. Proteomics 2003, 3, 2142-2146.
22. Sheehan, K., Calvert, V. S., Kay, E. W. L. Y., Fishman, D. et al., Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma. Mol. Cell Proteomics 2005, 4, 364-355.
23. Jiang, R. C., Mircean, C., Shmulevich, I., Cogdell, D. et al., Pathway alterations during glioma progression revealed by reverse phase protein lysate arrays. Proteomics 2006, 6, 2964-2971.
24. Tibes, R., Lu, Y. L., Giles, F., Estey, E. H. et al., Reverse phase protein array (RPPA): Validation of a novel proteomic technology and utility for analysis of primary leukemia specimens. Clin. Cancer Res. 2005, 11, 9163S-9164S.
25. Rapkiewicz, A., Espina, V., Zujewski, J. A., Lebowitz, P. F. et al., The needle in the haystack: application of breast fine-needle aspirate samples to quantitative protein microarray technology. Cancer 2007, 111, 173-184.
26. Petricoin, E. F., Espina, V., Araujo, R. P., Midura, B. et al., Phosphoprotein pathway mapping: Akt/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival. Cancer Res. 2007, 67, 3431-3440.
27. Haller, F., Loebke, C., Ruschhaupt, M., Schulten, H. J. et al., Loss of 9p leads to p16INK4A down-regulation and enables RB/ E2F1-dependent cell cycle promotion in gastrointestinal stromal tumours (GISTs). J. Pathol. 2008, 215, 253-262.
28. Gunawan, B., von Heydebreck, A., Sander, B., Schulten, H. J. et al., An oncogenetic tree model in gastrointestinal stromal tumours (GISTs) identifies different pathways of cytogenetic evolution with prognostic implications. J. Pathol. 2007, 211, 463-470.
29. Harari, D., Yarden, Y., Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. Oncogene 2000, 19, 6102-6114.
30. Ford, A. C., Grandis, J. R., Targeting epidermal growth factor receptor in head and neck cancer. Head Neck 2003, 25, 67-73.
31. Citri, A., Yarden, Y., EGF-ERBB signalling: towards the systems level. Nat. Rev. Mol. Cell Biol. 2006, 7, 505-516.
32. VanMeter, A. J., Rodriguez, A. S., Bowman, E. D., Jen, J. et al., Laser capture microdissection and protein microarray analysis of human non-small cell lung cancer: differential epidermal growth factor receptor (EGFR) phosphorylation events associated with mutated EGFR compared with wild type. Mol. Cell Proteomics 2008, 7, 1902-1924.
33. Wulfkuhle, J. D., Speer, R., Pierobon, M., Laird, J. et al., Multiplexed cell signaling analysis of human breast cancer applications for personalized therapy. J. Proteome Res. 2008, 7, 1508-1517.
34. Joensuu, H., Roberts, P. J., Sarlomo-Rikala, M., Andersson, L. C. et al., Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N. Engl. J. Med. 2001, 344, 1052-1056.
35. Haller, F., Loebke, C., Ruschhaupt, M., Schulten, H. J. et al., Increased KIT signalling with up-regulation of cyclin D correlates to accelerated proliferation and shorter disease-free survival in gastrointestinal stromal tumours (GISTs) with KIT exon 11 deletions. J. Pathol. 2008, 216, 225-235.
36. Heinrich, M. C., Corless, C. L., Demetri, G. D., Blanke, C. D. et al., Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J. Clin. Oncol. 2003, 21, 4342-4349.
37. Miettinen, M., El-Rifai, W., Sobin, L. H., Lasota, J., Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: A review. Human Pathol. 2002, 33, 478-483.
38. Ciardiello, F., Tortora, G., A novel approach in the treatment of cancer: Targeting the epidermal growth factor receptor. Clin. Cancer. Res. 2001, 7, 2958-2970.
39. Heinrich, M. C., Blanke, C. D., Druker, B. J., Corless, C. L., Inhibition of KIT tyrosine kinase activity: A novel molecular Proteomics Clin. Appl. 2009, 3, 1140-1150 1149 approach to the treatment of KIT-positive malignancies. J. Clin. Oncol. 2002, 20, 1692-1703.
40. Hidalgo, M., Eckhardt, S. G., Development of matrix metalloproteinase inhibitors in cancer therapy. J. Natl. Cancer Inst. 2001, 93, 178-193.
41. Janne, P. A., Engelman, J. A., Johnson, B. E., Epidermal growth factor receptor mutations in non-small-cell lung cancer: Implications for treatment and tumor biology. J. Clin. Oncol. 2005, 23, 3227-3234.
42. Senderowicz, A. M., Small-molecule cyclin-dependent kinase modulators. Oncogene 2003, 22, 6609-6620.
43. Morgillo, F., Lee, H. Y., Resistance to epidermal growth factor receptor-targeted therapy. Drug Resist. Updat. 2005, 8, 298-310.
44. Kornblau, S. M., Tibes, R., Qiu, Y., Chen, W. et al., Functional proteomic profiling of AML predicts response and survival. Blood 2009, 113, 154-164.
45. Vogelstein, B., Kinzler, K. W., The Multistep Nature of Cancer. Trends Genet. 1993, 9, 138-141.
46. Castellano, E., De las Rivas, J., Guerrero, C., Santos, E., Transcriptional networks of knockout cell lines identify functional specificities of H-Ras and N-Ras: significant involvement of N-Ras in biotic and defense responses. Oncogene 2007, 26, 917-933.
47. Akkiprik, M., Nicorici, D., Cogdell, D., Jia, Y. J. et al., Dissection of signaling pathways in fourteen breast cancer cell lines using reverse-phase protein lysate microarray. Technol. Cancer Res. Treat. 2006, 5, 543-551.
48. Boyd, Z. S., Wu, Q. J., O'Brien, C., Spoerke, J. et al., Proteomic analysis of breast cancer molecular subtypes and biomarkers of response to targeted kinase inhibitors using reverse-phase protein microarrays. Mol. Cancer Ther. 2008, 7, 3695-3706.
49. Nishizuka, S., Chen, S. T., Gwadry, F. G., Alexander, J. et al., Diagnostic markers that distinguish colon and ovarian adenocarcinomas: identification by genomic, proteomic, and tissue array profiling. Cancer Res. 2003, 63, 5243-5250.
50. Fire, A., RNA-triggered gene silencing. Trends Genet. 1999, 15, 358-363.
51. Walter, N., Schwille, P., Eigen, M., Fluorescence correlation analysis of probe diffusion simplifies quantitative pathogen detection by PCR. Proc. Natl. Acad. Sci. USA 1996, 93, 12805-12810.
52. Sahin, O., Lobke, C., Korf, U., Appelhans, H. et al., Combinatorial RNAi for quantitative protein network analysis. Proc. Natl. Acad. Sci. USA 2007, 104, 6579-6584.
53. Grimm, D., Kay, M. A., Combinatorial RNAi: A winning strategy for the race against evolving targets? Mol. Ther. 2007, 15, 878-888.
54. Liu, G., Wong-Staal, F., QX.,L., Development of new RNAi therapeutics. Histol. Histopathol. 2007, 22, 211-217.
55. Sahin, O., Frohlich, H., C,L., Korf, U. et al., Modeling ERBB receptor-regulated G1/S transition to find novel targets for de novo trastuzumab resistance. BMC Syst. Biol. 2009, 3, 1.
56. Pawlak, M., Schick, E., Bopp, M. A., Schneider, M. J. et al., Zeptosens' protein microarrays: A novel high performance microarray platform for low abundance protein analysis. Proteomics 2002, 2, 383-393.
57. Loebke, C., Sueltmann, H., Schmidt, C., Henjes, F. et al., Infrared-based protein detection arrays for quantitative proteomics. Proteomics 2007, 7, 558-564.
58. Calvert, V., Tang, Y., Boveia, V., Wulfkuhle, J. et al., Development of multiplexed protein profiling and detection using near infrared detection of reverse-phase protein microarrays. Clin. Proteomics J. 2004, 1, 81-89.
59. Espina, V., Edmiston, K. H., Heiby, M., Pierobon, M. et al., A portrait of tissue phosphoprotein stability in the clinical tissue procurement process. Mol. Cell Proteomics 2008, 7, 1998-2018.
60. Barclay, D., Zamora, R., Torres, A., Namas, R. et al., A simple, rapid, and convenient Luminex-compatible method of tissue isolation. J. Clin. Lab. Anal. 2008, 22, 278-281.
61. Nishizuka, S., Charboneau, L., Young, L., Major, S. et al., Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays. Proc. Natl. Acad. Sci. USA 2003, 100, 14229-14234.
62. Berglund, L., Bjöerling, E., Oksvold, P., Fagerberg, L. et al., A genecentric human protein atlas for expression profiles based on antibodies. Mol. Cell Proteomics 2008, 7, 2019-2027.
63. Björling, E., Uhlén, M., Antibodypedia, a portal for sharing antibody and antigen validation data. Mol. Cell Proteomics 2008, 7, 2028-2037.
64. Paavilainen, L., Wernerus, H., Nilsson, P., Uhlen, M. et al., Evaluation of monospecific antibodies - a comparison study with commercial analogs using immunohistochemistry on tissue microarrays. Appl. Immunohistochem. Mol. Morphol. 2008, 16, 493-502.
65. Tibes, R., Qiu, Y. H., Hennessy, B., Andreeff, M. et al., Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol. Cancer Ther. 2006, 5, 2512-2521.
66. Liotta, L. A., Espina, V., Mehta, A. I., Calvert, V. et al., Protein microarrays: meeting analytical challenges for clinical applications. Cancer Cell 2003, 3, 317-325.
67. Hanahan, D., Weinberg, R. A., The hallmarks of cancer. Cell 2000, 100, 57-70.